• Core operations transitioned to phytocannabinoid-based therapies
• Four trial candidates targeting chronic pain, Alzheimer’s and other conditions
• Unique approach combining existing therapies with cannabinoids

India Globalization Capital, Inc. (NYSE MKT: IGC) is developing disruptive new pharmaceutical therapies to fight a variety of ailments. Currently, the Maryland-based corporation has a pipeline of cannabis-based combination candidates under development to treat Alzheimer’s disease, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy. Supporting this effort, the company has put together a robust intellectual property (IP) portfolio. IGC intends nothing less than to become a leading specialty provider of phytocannabinoid-based pharmaceuticals and complimentary alternative medicine (CAM) nutraceutical products. Operating in the world’s fastest growing industry (cannabis) with its novel ‘something old, something new’ approach, IGC could soon expect its valuation to rise in line with peers like Corbus Pharmaceuticals (NASDAQ: CRBP), Anavex Life Sciences (NASDAQ: AVXL) and Zynerba Pharmaceuticals (NASDAQ: ZYNE).

IGC recently disposed of its low-margin iron ore and electronic trading businesses. With that divestment, the company is now focused on its long-term goal of becoming a heavyweight in the cannabis space. To achieve its objective of being a major player of cannabinoid combination therapies, IGC is actively engaged in planning the development pathways for its four product candidates.

IGC-501 heads IGC’s quartet of pipeline candidates. In September 2015, the company filed a Patent Cooperation Treaty (PCT) application for the therapy, which addresses neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. At present, such indications tend to be treated with opioids, which are notoriously addictive. However, the alarming rise and devastating effects of opioid abuse are driving the search for less pernicious alternatives. In the U.S. alone, this presents a market opportunity of around $25 billion.

A PCT filing has also been made for IGC-502, designed to treat canine seizures, which affect about five percent of dogs. Additionally, in August 2016, the company filed for a therapy to treat cachexia, which it has designated IGC-504. Also known as wasting syndrome, cachexia affects about 1.3 million in the U.S. It is a condition that’s typically associated with cancer, multiple sclerosis (MS), Parkinson’s, and HIV/AIDS.

In June 2017, IGC announced it had entered into a definitive agreement with the University of South Florida making IGC the exclusive licensee of the U.S. patent filing entitled “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” This agreement gives IGC a way to enter a huge market for what has been called ‘America’s most expensive disease.’ For 2017, Medicare and Medicaid expenditures for treating Alzheimer’s are expected to reach $175 billion. Currently, over 5.3 million Americans suffer from the condition, and that number is expected to double over the next 20 years.

The drug candidate IGC-ADI explores an alternative way delta 9-tetrahydrocannabinol (THC) interacts with the human body. Several pathways have already been identified, including binding to the CB1 receptor, anti-oxidative effects, and others, but IGC-ADI works through a different molecular pathway that allows low doses of THC to bind to amyloid beta plaques and prevent those plaques from aggregating on neurons, which causes the cognitive decline that results in Alzheimer’s disease. If approved, this patent will give IGC a significant proprietary interest in a unique way to treat Alzheimer’s disease. THC is the psychotropic phytocannabinoid mainly responsible for the ‘high’ of cannabis, although, it must be noted, other cannabinoids such as cannabinol (CBN) and tetrahydrocannabivarin (THCV) are psychotropic. The treatment of Alzheimer’s is a lucrative market opportunity, and pharma companies operating in that space are experiencing significant valuations. Anavex Life Sciences, which currently has a candidate in a Phase IIa clinical trial for Alzheimer’s disease, has a market cap of around $179 million.

The same is true of companies developing cannabinoid-based treatments. Corbus Pharmaceuticals, which presently has programs assessing its oral endocannabinoid-mimetic drug candidate for treating a variety of ailments, has a current market cap of around $310 million, and Zynerba, which is also developing synthetic cannabinoids, has a market cap of about $235 million at present. IGC, trading presently at $0.40, has a market cap of about $12 million, a valuation that is unlikely to stay that low for long.

For more information, visit the company’s website at www.IGCInc.us

• Poised for rapid revenue development following acquisition of MediaPlay
• Agreements in place with leading application stores to fast-track applications
• Company had $589,000 in revenues in 2016 and was able to eliminate more than $500,000 in corporate debt

Technology development and incubation acceleration company AppSwarm, Inc. (OTC: SWRM) has announced its acquisition of MediaPlay, a multiplatform games publisher and developer (http://dtn.fm/QM3ia). The company has further announced the creation of two AppSwarm divisions.

Assets purchased as part of the acquisition include:

• Games in-house
• Rights to games currently in negotiations
• Pending letters of intent
• Pending distribution agreements
• Work-for-hire contracts

MediaPlay has a special focus on free-to-play mobile games and is led by a core team composed of veterans of the game industry who have made successful exits in previous ventures and have held executive positions with some of the world’s largest gaming companies, such as Electronic Arts, Kabam and Activision. Collectively, the MediaPlay team is responsible for the launch of more than seven companies.

Historically, MediaPlay’s team has created organic growth by developing some of its own products, as well as through third-party acquisitions of branded games. The MediaPlay team has had tremendous ongoing success and has had its games featured by Apple and Google multiple times. The team executed a three-game development and publishing agreement with Discovery Networks in 2016 and has made subsequent deals with Valiant Entertainment and other brands.

AppSwarm anticipates rapid revenue development within the next 24 months as a result of this acquisition. MediaPlay brings an acute focus on nurtured relationships and international contacts, as well as a proven ability to bring about major corporate developments and publishing agreements.

The acquisition further enables AppSwarm to form two distinct but synergistic gaming divisions and revenue streams. The company’s current efforts will be focused on the application Incubation and Acquisition Division, which includes gaming opportunities, interactive developments and e-commerce business solutions.

Focused on partnering with app developers, AppSwarm is engaged in accelerating the development of free-to-play mobile games and fast-tracking them to the market. The company partners with game developers through joint ventures, royalty agreements, marketing partnerships and outright purchases.

AppSwarm actively reaches out to budding, entrepreneurial-minded application developers with great ideas who lack the knowledge to effectively market their products. When the company identifies an application with potential, the person or firm that created the app is approached by AppSwarm for the purposes of negotiating a stock purchase agreement, royalty agreement, joint venture, partnership or outright purchase.

AppSwarm has enviable financial resources to help market applications in the most effective ways. The company uses all forms of social marketing, along with traditional marketing, to get an app before as many eyes as possible. AppSwarm further has agreements in place with the foremost application stores, enabling the company to fast-track its applications.

In 2016, AppSwarm had revenues of $589,000, and the company was able to eliminate well over $500,000 in corporate debt. This enabled AppSwarm to commence 2017 with the momentum to complete synergistic mergers and acquisitions, such as the acquisition of MediaPlay.

For more information, visit the company’s website at www.App-Swarm.com

Let us hear your thoughts: AppSwarm, Inc. Message Board

• Payment solutions for cannabis industry
• Operator of cryptocurrency exchange
• Bitcoin payment solutions for retailers

In its latest initiatives, SinglePoint, Inc. (OTC: SING) is showing that innovation, like politics, makes strange bedfellows. This diversified holding company specializing in acquisitions of small to mid-sized companies, with an emphasis on new technologies, is planning a marriage of cannabis and cryptocurrencies, both of which are rapidly growing opportunities. The company is developing a payment processing solution utilizing cryptocurrencies that is likely to find early application in the cannabis industry. Using its recently acquired $Weed and other cryptocurrencies, SinglePoint wants to help the cannabis industry solve its payment problems.

Although licensed by their state authorities, medical marijuana dispensaries and other cannabis retailers find it difficult to maintain merchant banking accounts at federally regulated financial institutions. The latter, fearful of violating the Controlled Substances Act, will typically cease operating an account if they discover it is associated with a business that ‘touches the plant’. Consequently, cannabis businesses are forced to deal in cash and face the attendant risk of burglaries and holdups. Additionally, customers cannot use their debit and credit cards, and all this because the regular financial system is federally regulated.

Cryptocurrencies, however, are not, and so they offer a ready-made solution to payment problems confronting high risk industries. The best known of these is undoubtedly bitcoin, the fortunes of which continue to improve, according to a recent MarketWatch report (http://dtn.fm/btcW9). Its authors discuss the high positive correlation between bitcoin prices and Google search trends for the word ‘bitcoin’, dubbed ‘a virtuous Satoshi cycle’ by Chris Burniske, who first observed it. Burniske is a bitcoin expert, previously a blockchain analyst at ARK Invest. Recent bitcoin prices have been stratospheric, with the price of a single bitcoin hitting a record high of $4,483.55 recently. Consumers who opt for a cryptocurrency wallet (part of the SinglePoint payment solution) will not only increase their payment options but their holdings of an asset that just keeps climbing in value.

SinglePoint has been working on a cryptocurrency solution for some time. Early in August, the company announced its purchase of the $Weed cryptocurrency from joint venture partner First Bitcoin Capital (OTC: BITCF). Known also as WeedCoin, the digital currency is currently listed on three exchanges, and SinglePoint intends to list and market the currency on more exchanges in the future. The recent initial coin offering (ICO) launch for the $Weed cryptocurrency resulted in an impressive market cap of close to $60 million.

In addition, SinglePoint intends to market its $Weed wallet to cannabis customers before they even set foot in the store. If successful, these efforts will address one of the largest barriers relating to the use of cryptocurrency at cannabis retail stores, i.e., consumers without a wallet who want to make a purchase. SinglePoint believes that, with proper execution, users of its $Weed cryptocurrency could enjoy a similar experience to the one offered to users of Starbucks’ mobile payment system, with payments completed through a simple scan of a barcode on the user’s smartphone or tablet.

For more information, visit the company’s website at www.SinglePoint.com

Let us hear your thoughts: SinglePoint, Inc. Message Board

• Booking engine as a B2B product set to drive growth
• NASDAQ listing in sight
• Fresh capital injection of $3 million

With the completion of its proprietary booking engine late last year, Monaker Group, Inc. (OTCQB: MKGI) has moved closer to realizing its motto: Travel Made Easy. Now the technology-driven travel company is intensifying its focus on delivering innovation to the alternative lodging rental (ALR) market and, to do so, has bolstered its balance sheet. The company has closed a round of financing with institutional and accredited investors (http://dtn.fm/i2DGk). The funds are earmarked to expand the B2B white label potential of the booking engine and to get the company ready for a listing on the NASDAQ.

Booking engines are the latest iteration by the travel industry to increase access and choice to consumers. They represent the current stage of developments that began in the post-WWII era, when American Airlines (AA) developed the industry’s first automated booking system. Its esoteric name, “Electromechanical Reservisor” (ER), might have puzzled the average traveler if he were allowed access to it, but he was not. Neither were travel agents. Only AA’s airline personnel could access the ER. The airline followed up the ER system, in 1953, with the tongue-twisting Semi-Automatic Business Research Environment reservation system (SABRE).

AA’s success in the reservation business meant that other airlines needed to follow suit to remain competitive. As a result, United Airlines launched Apollo; Delta Airlines came up with DATAS; and Trans World Airlines responded with PARS. These were all proprietary, silo systems, owned and used exclusively by the airlines that developed them, and they were not linked to each other.

By the 1970s, airlines were seeing the advantages of allowing travel agents access to their systems. As a result, the in-house reservation systems morphed into what became known as computer reservation systems (CRS), through which travel agents could query and make reservations. Soon, third party entities hit on the idea of linking separate computer reservation systems, and global distribution systems (GDS) were born. GDS offered travel agents access to the inventory of all the main airlines. Now that agents were part and parcel of the network, the obvious next step was to offer the traveler himself access through a booking engine.

Through a booking engine, a would-be traveler can specify his or her travel requirements such as point of departure, departure date, destination, return date and class of travel. In response, the booking engine will offer airline seats, hotel rooms, alternative accommodation and a variety of related offerings that fit the bill. This is definitely travel made easy.

Monaker expects that most of its growth in the future will come from offering its booking engine as a B2B white label “Alternative Lodging” “Vacation Rental” product to established providers, such as online travel agencies (OTAs) and cruise providers, particularly since it offers “Instant Booking”. Instant Booking allows travelers to initiate a booking and receive an instant confirmation.

Monaker recently completed a private placement of equity with a group of institutional and accredited individual investors for gross proceeds of $3 million. Certain insiders and board members also participated in the offering, representing $635,000, or approximately 21 percent of the offered amount. Part of the proceeds will go toward further development of its booking engine, which forms the core of Monaker’s alternative lodging rental platform. The fresh capital will also facilitate the company’s efforts to be listed on the NASDAQ, which are presently underway.

For more information, visit the company’s website at www.MonakerGroup.com

• Disruptive, patented technology is set to revolutionize the edible cannabis market
• Company has patent applications in 45 countries, including 18 applications in the U.S.
• Technology is patent-protected for CBD and all other non-psychoactive cannabinoids, with patents pending for THC, other psychoactive cannabinoids, NSAIDs, nicotine and other molecules

A common complaint among the consumers of cannabis edibles is an unpleasant taste that can often be detected, but that unpleasant taste and other inadequacies of cannabis edibles are being overcome thanks to the incredible innovations of Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP).

Lexaria is literally bringing new flavor to the marijuana industry with its disruptive process, which masks the unpleasant taste associated with cannabis. Lexaria’s lipophilic enhancement technology also changes the way cannabinoids enter the body; substantially speeds up the time frame in which tetrahydrocannabinol (THC) effects can be felt after consuming a cannabinoid edible; and increases bio-absorption by up to 10 times, making the absorption from cannabis edibles equal to the absorption from inhaled cannabis.

Because cannabinoids are absorbed poorly by the gastrointestinal tract, many cannabis users turn to other administration routes, like smoking, for greater effectiveness. Lexaria’s proprietary technology for better delivery of bioactive compounds solves the problem of poor absorption, increasing the bio-absorption of cannabis edibles by between five and tenfold. The effects of the THC from an edible product created using Lexaria’s patented process are also felt much more quickly—taking effect within 15-20 minutes as opposed to one to two hours.

The possibilities enabled by Lexaria’s technology are multifold and exciting. For instance, excessive amounts of sugar have previously had to be included in cannabis edibles to mask the unwanted taste, but because Lexaria’s technology eliminates that undesirable flavor, zero-sugar formats are now possible for cannabinoid edibles.

Lexaria’s process involves taking the healthy cocktail of molecules found in the company’s organically sourced hemp and infusing those molecules inside the molecules of other ingredients. Lexaria works with lipids, because the endocannabinoid system in the human body is lipid-based. The company has found its method to be a more efficient means of delivering hemp oil ingredients to the body, making a small amount of hemp seed oil inside a Lexaria product equal to a great deal of hemp oil delivered via a product that wasn’t created using the company’s revolutionary technology.

Lexaria’s pioneering technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids. Patents are further pending for THC and other psychoactive cannabinoids, along with nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. In the United States, 18 patent applications have been filed, and international and national patent filings have been made in 44 other countries.

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

• One of first licensed medical cannabis producers in Canada
• $15 million equity investment starts construction of new 50,000 square foot facility
• Production to quadruple in booming market

Legal since 2001, medical cannabis operations in Canada changed dramatically about a year ago when the Access to Cannabis for Medical Purposes Regulations (ACMPR) went into effect. Health Canada now strictly oversees licensing, monitoring and compliance of commercial medical cannabis producers. Health Canada conducts thorough reviews of applications to ensure compliance with the regulations and works closely with producers once licensed to monitor and ensure compliance with such strictures as personnel security measures, good production practices, packaging, shipping, record keeping and import and export requirements. Licenses are difficult to acquire, and frequent inspections hold producers to stringent standards.

One of the very first licensed producers and a pioneer in Canadian medical cannabis, ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) has always held to meticulous specifications in the production of its pharmaceutical grade, plant-based medicines. Maintaining standards designed to exceed government requirements, ABcann grows plants only in small batches in order to create controllable, consistent and predictable yields. The plants are nurtured in controlled environmental chambers to deliver dependable results with each harvest. Chemical and pesticide free, ABcann produces medical cannabis that effectuates the same medical response with every use.

Medical cannabis business is booming in Canada. The number of medical marijuana patients continues to grow rapidly, increasing nearly 30 percent in the first quarter of this year, while sales of medical cannabis increased over 24 percent from last year. The growth trajectory shows no signs of slowing, and, given the licensing process and stringent inspections, licensed producers already in production are well positioned to reap substantial rewards.

Given ABcann’s underlying value, the recent announcement by Cannabis Wheaton Income Corp. (TSX.V: CBW) comes as little surprise. In a July 28th press release, Cannabis Wheaton, which invests in and supports a wide range of cannabis cultivation companies, announced Exchange approval for its purchase of $15 million of common shares of ABcann Global at $2.25 per share. This initial investment is part of a larger phased investment for the construction of an additional 50,000 square feet of pure cultivation space next to ABcann’s current 14,000 square foot cannabis cultivation facility in Ontario, Canada.

With a market capitalization around $82 million, ABcann presents great value for Cannabis Wheaton. Other Canadian licensed producers carry much higher market valuations. Emblem Corp., with nearly the same sized facility as ABcann, trades around the two dollar mark and carries a $170+ million market cap. Supreme Pharmaceuticals has a $250 million cap, and Hydropothecary Corporation maintains a $150 million cap, even after a voluntary stop-sale / stop-shipment when evidence of unapproved fungicide was found in its products. Cannabis Wheaton’s minority stake in ABcann looks to be a steal.

ABcann has already invested over $20 million in ongoing operations and international expansion plans. The company currently owns and operates a 14,000 square foot state-of-the-art facility. It also owns an adjoining 50 acres of land that’s slated for construction of the new 50,000 square foot production facility financed by Cannabis Wheaton’s equity investment. The additional cultivation space at the new facility is anticipated to provide Cannabis Wheaton with an estimated eight million grams of cannabis per year, while its equity position in ABcann should pay off handsomely as well.

ABcann’s proprietary cultivation methods already produce high quality cannabis with industry leading yields, and this latest announcement is a testament to ABcann’s future. The Canadian government recently stated that it will press ahead in 2017 with plans to legalize marijuana for adult recreational use. That market is expected to be worth $5 billion a year by 2020, according to leading industry analysts. This latest investment in ABcann appears both well timed and financially prescient.

For more information, visit the company’s website at www.ABcann.ca

Let us hear your thoughts: ABcann Global Corp. Message Board

• The new company is restructured and rebranded for international growth, both by acquisition and organically
• Moves follow the company’s name and symbol change announced on August 4, 2017
• Campbell, charged with spearheading the global growth of the new company, sets five-year strategy

HighCom Global Security, Inc. (OTC: HCGS) has named Craig B. Campbell as its new chief executive officer, appointed a new board of directors and reorganized its wholly owned subsidiary. As it transitions to an international company, these changes coordinate with its prior name and symbol change (http://dtn.fm/fT2rL).

The Columbus, Ohio-based firm provides to the security and defense industries a complete line of equipment and services. The new structure will enable the company to grow internationally. Its subsidiary, HighCom Security, Inc., will be divided into two segments: HighCom Armor Solutions, Inc., and Blastgard Technologies, Inc.

“We are pleased to announce the successful execution of our restructuring strategy to expand our international focus,” Campbell said in a news release. “HighCom Global’s brands and products are highly relevant to security and defense needs worldwide, and with the assemblage of a world-class board of directors, we have access to high-level industry experts, finance capital and business acumen which will support our strategic plan of growth, both vertical and horizontal, over several sectors in the security market.”

HighCom Armor Solutions, Inc. will serve the personal protective equipment market worldwide. HighCom Armor has marketed a line of OEM/private label products for the military and law enforcement agencies. Blastgard Technologies, Inc., will incorporate the proprietary BlastWrap® blast mitigation technology, unique products which suppress the impact of blasts and post-blast fires. It serves commercial, military, government and law enforcement entities.

A Harvard Business School alumnus, Campbell is an experienced entrepreneur with a proven record of expanding the security industry exponentially. He received the “Top 40 Under 40” award in Canada and was named an “Entrepreneur of the Year,” by Ernst & Young. He explained that the new company’s five-year goal for capital deployment and profitability is to minimize shareholder dilution while maximizing opportunities through diversification.

The new corporate structure and board will prepare the company to reach its goal of becoming a global leader in the security and safety industry. The announcement follows the August 4, 2017, company name and symbol changes (http://dtn.fm/g9sbG). The rebranding was made after the firm’s annual shareholder’s meeting in late July. The new corporate team is committed to capitalizing on future opportunities by expanding internationally through both acquisitions and organic growth, the company said.

Campbell will also serve as a member of the new board of directors. Others named are:

• Paul Sparkes, board chairman, has extensive experience in media, government, finance and public affairs
• Curt Cronin serves as CEO of Kaizen International and was formerly a Navy SEAL Commander. Kaizen International works with the world’s largest and most dynamic companies to drive extraordinary success on an accelerated timeframe.
• Andrew Blott, who has a record of growing small- and medium-sized companies, is a financial and business professional established on both Wall Street and Bay Street
• Bill Buckley, also an alumnus of Harvard Business School, has both a degree in mechanical engineering and an MBA . He has succeeded in multiple entities and is a business executive with vast experience in high level, large-cap companies

For more information, visit the company’s website at www.HighComSecurity.com

Let us hear your thoughts: HighCom Global Security, Inc. Message Board

• India Globalization Capital recently acquired exclusive patent rights for the use of low-dose THC as a potential therapeutic agent for Alzheimer’s disease
• No other publicly traded cannabis pharmaceutical company has a patent filing for a potential Alzheimer’s treatment
• Costs associated with Alzheimer’s disease top $236 billion in the U.S. and $600 billion globally

India Globalization Capital, Inc. (NYSE MKT: IGC), a Maryland-based company, is currently preparing four products for medical trials, including Hyalolex for the treatment of Alzheimer’s disease. Alzheimer’s is a fatal, progressive brain disease that slowly destroys memory and thinking.

Alzheimer’s is the leading cause of dementia and the third-leading cause of death in the U.S. Treatment outlooks have been bleak, as there is currently no cure, no way to prevent the disease, and no long-term treatment for the disease. However, India Globalization Capital may well improve the outlook for Alzheimer’s patients with a novel cannabis-based pharmaceutical therapy.

From an investment standpoint, IGC’s potential for market valuation growth is striking due to the size of the market for a successful Alzheimer’s treatment. Other companies in the cannabis space and also those focused on treatments for Alzheimer’s are valued in the hundreds of millions – and even billions – of dollars.

A definitive licensing agreement with the University of South Florida makes IGC the exclusive licensee of a U.S. patent filing titled, “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” The patent filing targets amyloid beta plaques, believed to be the cause of Alzheimer’s disease. The patent asserts that a newly discovered pathway allows low doses of THC to bind to amyloid beta plaques and keep them from accumulating on neurons, thus impacting the disease’s notorious cognitive decline. Be sure to view the CNN video on IGC’s website for additional information- http://www.igcinc.us/alzheimers-disease-1.

India Globalization Capital is preparing other phytocannabinoid-based pharmaceutical therapies for medical trials that target nausea and vomiting in AIDS and cancer patients; sleep disorders, anxiety and dyskinesia in Parkinson’s patients; and seizures in dogs and cats.

In addition, the company is developing treatments aimed at neuropathic and cancer pain, epilepsy, PTSD, end-of-life supportive care, and therapies for chronic neurological and cancer diagnoses.

India Globalization Capital is a first mover in the area of cannabis-based combination therapy and has filed for six patents in large market treatments including pain, eating disorders and epilepsy. Patents have been filed for a pain medication in the U.S., Canada and Europe, and upcoming filings include therapies aimed at PTSD, depression, Alzheimer’s and Parkinson’s disease.

For more information, visit www.IGCInc.us

• Cannabis is fastest-growing industry in North America
• Canada’s cannabis market is ripe for explosive growth
• Algae Dynamics carving out niche in explosive market

The fastest-growing industry with the most consistent growth rate in North America is legal marijuana. A recent Forbes article says that the market could grow 700% by 2020 (http://dtn.fm/8RMvi). Investors have become acutely aware, which explains the movement in some marijuana stocks that have risen dramatically over the last 18 months.

According to ArcView, a well-known cannabis research firm, North American sales of legal medical and recreational cannabis soared 34% in 2016 to $6.9 billion. These markets are expected to continue to grow at a blistering pace of over 25 percent annually through 2021, reaching approximately $22 billion. Growth is expected to come from further jurisdictional expansion of legalization, plus rapid organic growth in areas where the drug is already legal. Mexico recently legalized medical cannabis throughout the country, and, in Canada, the number of eligible medical patients has been growing at a pace of almost 10% per month, according to Health Canada. Canada’s government has also introduced legislation to make recreational marijuana legal across the country by this time next year.

A professional consulting group hired to assess Canada’s proposed recreational marijuana market says that jurisdictions that regulate cannabis should expect “unbelievably high” sales growth in the first few years as criminals are driven out of business (http://dtn.fm/Q6ucS). Not yet authorized to discuss findings on future Canadian cannabis markets because of contracts with Health Canada, a look at the group’s estimates for Colorado’s regulated cannabis industry suggests that Canada can expect its own markets to generate billions of dollars per year in direct and indirect economic activity. While every jurisdiction is different, Canada’s population is seven times larger than that of Colorado, where regulated marijuana sales skyrocketed 42 percent between 2014 and 2015 and totaled nearly $1 billion. Numbers out of Canada could easily be seven to 10 times as much as Colorado.

Many of the better known marijuana stocks have already moved in anticipation of the forthcoming windfall of business. The way to make money on this incoming avalanche of revenues is to find and exploit a niche market, which is exactly what Algae Dynamics Corp. (OTCQB: ADYNF) is in the midst of undertaking. Algae Dynamics is focused on the extraction of oils from hemp, cannabis and algae for use in unique health products and pharmaceuticals. The company has already engaged two highly respected universities to provide research into the various uses of cannabis and hemp oil extracts, which, in combination with other compounds, may prove effective in treating cancers of the colon-rectum, pancreas, breast and prostate, as well as for the development of novel pharmacotherapies for various mental health maladies.

With medical marijuana already legal in Canada, Algae Dynamics is carving out a lucrative niche in an explosive market and is positioned to succeed. However, the legalization of recreational marijuana could propel the company far beyond what one would normally expect. One would suspect the company of being prepared with product and processes to profit from recreational legalization as well. Cannabis sales in Colorado soared 42 percent in the year recreational use was allowed. Canada’s cannabis markets and Algae Dynamics’ endeavors could hit some amazing numbers and exceed even that eye-popping growth rate.

For more information, visit the company’s website at www.AlgaeDynamics.com

Let us hear your thoughts: Algae Dynamics Corp. Message Board

• Adjusted EBITDA increases 54% in quarter to $4.8 million
• Cogint’s information services segment revenues rose 39% in quarter
• Pay Per Call, a new product, generated $1.5 million in additional sales in 2Q2017, as wide range of ‘vertical’ clients adopted it

Cogint, Inc. (NASDAQ: COGT) revenues reached $53 million for the second quarter ended June 30, 2017, a 29% rise as compared to the same period in 2016. Sales for the first half of 2017 ended the same date increased to $103.8 million, also a 29% spike from the prior year, the company announced (http://dtn.fm/aq9Ll).

Cogint is a cloud-based data analytics company with proprietary algorithm technology platforms, such as CORE™ and Agile Audience Engine™, which are applicable to a multitude of industries. The company’s goal is to achieve return-on-investment driven results for clients. The firm uses data fusion and customized analytics to help clients manage risk, identify fraud and abuse, collect debts and acquire new customers.

In a news release, Derek Dubner, chief executive officer of Cogint, said, “We delivered a very strong quarter with revenues of $53 million, up 29% versus the second quarter of 2016, and adjusted EBITDA of $4.8 million, up 54%, driven by enterprise-wide adoption of our products and solutions. Given our innovative-driven product roadmap and the increasing momentum we experienced throughout the quarter, we are very optimistic about the second half of 2017.”

Key to the gains were a 39% jump in sales within information services, a 24% boost in performance marketing and revenue from its new Pay Per Call ad format, which was introduced in December 2016 and generated $1.5 million in additional sales in 2Q2017.

CORE™ is the company’s own next-generation data fusion platform, applicable to a variety of industries. These range from insurance and financial services companies to law enforcement, health care, law firms, government and others.

The Agile Audience Engine™ assists retailers, brands and marketers with customer identification on a massive scale. It targets consumers through personal identification information for the packaged goods, financial services and entertainment industries, among others. What helps make Cogint unique in this sector is its high 80% use of mobile devices for consumer interaction.

For more information, visit the company website at www.Cogint.com